Sullivan Mark
Chief Legal Officer
Sullivan Mark has filed 7 SEC Form 4 filings (7 transaction rows) across 2 companies, including DFTX, MNMD, with disclosures dating back to 2025. 7 of those filings fall inside the rolling window. Most recent filing: Aug 12, 2026.
On the most recent filing, Sullivan Mark is listed as Chief Legal Officer at Definium Therapeutics, Inc. Inside the rolling window, Sullivan Mark reported no open-market purchases and 4 open-market sales totaling $1.0M in DFTX and MNMD. The largest disclosed transaction in the window is a sale of 13,008 DFTX shares on Jun 25, 2026, worth $586K.
Companies traded
Other insiders at DFTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$1.0M
reported sales (SEC code S)
Companies
2
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Sullivan Mark made?
Sullivan Mark has filed 7 SEC Form 4 filings (7 transaction rows) across 2 companies, including DFTX, MNMD since 2025.
Which companies does Sullivan Mark trade?
Sullivan Mark has filed SEC Form 4 disclosures for 2 companies, including DFTX, MNMD.
When was Sullivan Mark's most recent SEC Form 4 filing?
Sullivan Mark's most recent SEC Form 4 filing on Tracefour is dated Aug 12, 2026.
What is Sullivan Mark's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Sullivan Mark is listed as Chief Legal Officer.
What is Sullivan Mark's total buy and sell value in the current window?
Inside the rolling retention window, Sullivan Mark bought $0 and sold $1.0M based on SEC Form 4 filings.
What was Sullivan Mark's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 13,008 DFTX shares on 2026-06-25, worth $586K, per SEC Form 4 filings.